Corrigendum to "Improving the environmental impact paradox of clinical medical laboratories" [Clin. Biochem. 141 (2026) 111063] [0.03%]
关于“改进临床医学实验室的环境影响悖论”的勘误声明[ Clin. Biochem. 141 (2026) 111063 ]
Pernilla Sörme,Scott Weitze
Pernilla Sörme
Published Erratum
Clinical biochemistry. 2026 Feb 12:111091. DOI:10.1016/j.clinbiochem.2026.111091 2026
Serum zinc, copper, and the Zn/Cu ratio across the glycemic spectrum: evidence from an automated clinical chemistry platform [0.03%]
血糖谱系中的血清锌、铜及zn/cu比值：一项自动化临床化学平台的证据
Ufuk Sarıkaya,Şahabettin Selek,Alime Sarıkaya
Ufuk Sarıkaya
Objectives: The zinc-to-copper ratio (Zn/Cu) integrates the opposing redox and metabolic roles of zinc and copper and may offer additional value for stratifying glycemic risk in clinical practice. This study evaluated ser...
Application of thrombosis-related biomarkers in the diagnosis and thrombosis risk stratification of heparin-induced thrombocytopenia patients [0.03%]
血小板减少症患者的血栓形成相关生物标志物的应用
Huiping Wang,Pengju Lv,Chenxue Qu et al.
Huiping Wang et al.
Objective: To evaluate thrombomodulin (TM), thrombin-antithrombin complex (TAT), plasmin-α2-plasmin inhibitor complex (PIC), tissue-plasminogen activator-inhibitor complex (t-PAIC), and D-dimer for diagnosing heparin-ind...
Inter-laboratory variability in vancomycin measurement in an external quality assessment scheme 2016-2025 [0.03%]
2016至2025年万古霉素外部质量评估方案中的室间差异性分析报告
Anders Larsson,Jonathan Cedernaes,Mats B Eriksson et al.
Anders Larsson et al.
Introduction: Vancomycin is a critical antibiotic for treating severe Gram-positive infections. Due to its narrow therapeutic window, reliable plasma concentration measurements are essential for dose adjustment and avoidi...
Evidence-based extension of reagent shelf-life beyond expiry using patient-based moving averages, westgard sigma rules, and CLSI EP25 [0.03%]
基于患者数据的移动平均、Westgard六西格玛规则和CLSI EP25行动声明的试剂有效期延长方案
Mohamed Mokhtar Khelil,Tony Badrick
Mohamed Mokhtar Khelil
Background: Reagent stability is a significant determinant of analytical reliability in clinical laboratories. Post-expiry reagent use is often discouraged due to the potential risk of systematic bias; however, empirical ...
Autoantibody testing in neuromuscular medicine: assay technologies, interpretation, and clinical utility [0.03%]
神经肌肉病的自身抗体检测：试验技术、结果解读及临床应用价值
Tony Zhang,John R Mills,Divyanshu Dubey et al.
Tony Zhang et al.
Neuromuscular autoantibody testing is a component in the diagnosis and management of autoimmune neuromuscular disorders. These immune inflammatory diseases target antigens found in nerves, muscles, and neuromuscular junctions, and may occas...
α-Synuclein seed amplification assay methodology and performance in Parkinson's disease, lewy body dementia, and multiple system atrophy: A meta-analysis [0.03%]
帕金森病、路易体痴呆和多系统萎缩中α-突触核蛋白种子放大检测的方法学及效能：一项荟萃分析研究
Cyril Helbling,Serena Yeung,Mari L DeMarco
Cyril Helbling
Seed amplification assays have shown promise in research for accurate diagnosis of synucleinopathies. In consideration of clinical implementation, gaps in the literature include that performance data are frequently determined using clinical...
Silent electrolyte imbalance unmasked by paralysis: a case of hypokalemia in a middle-aged woman [0.03%]
中年女性麻痹性低钾血症1例报告
Aman Advani,Hassan Ahmed,Muhammad Ahsan Shabbir et al.
Aman Advani et al.
Background: Hypokalemic periodic paralysis is a rare autosomal dominant muscle channelopathy often misdiagnosed due to its atypical presentation. It is characterized by episodic flaccid paralysis with low serum potassium ...
Fibroblast growth factor 23-induced hypophosphatemia in a malignant phosphaturic mesenchymal tumor: presentation of a rare case [0.03%]
成骨不全型恶性磷尿性间叶瘤所致的纤维生长因子23诱导的低磷血症一例报告
Diver Alexis Chicangana Tuquerres,Andrés David Sastre Martinez,Carlos Mário Barrios Herrera et al.
Diver Alexis Chicangana Tuquerres et al.
Introduction: Tumor-induced osteomalacia is a rare paraneoplastic disorder caused by excess fibroblast growth factor 23 (FGF23), most often produced by phosphaturic mesenchymal tumors. Delayed diagnosis may result in seve...
The CDKN2A/B rs10811661 polymorphism is associated with metabolic syndrome, insulin resistance, and lipid levels in individuals with obesity and impaired fasting glucose [0.03%]
肥胖和空腹血糖受损患者中CDKN2A/B基因多态性与代谢综合征、胰岛素抵抗及血脂水平相关性研究
Daniel de Luis,Olatz Izaola,David Primo
Daniel de Luis
Background & aims: A significant association has been confirmed between the rs10811661 polymorphism in the CDKN2 gene, and increased susceptibility to type 2 diabetes. The present study aimed to investigate the associatio...